JPRN-UMIN000027223已完成未知
A phase II study of docetaxel plus ramcirumab with pegfilgrastim in treated patients with advanced non-small cell lung cancer - A phase II study of docetaxel plus ramcirumab with pegfilgrastim in treated patients with advanced non-small cell lung cancer
Osaka City University Department of Respiratory Medicine0 个研究点目标入组 28 人开始时间: 2017年5月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Interstitial pneumonia , fibroid lung confirmed by CT. 2)History of serious drug allergy 3)Patient with much ascetic fluid, pleural effusion, cardiac effusion. 4)Obvious tumor invasion to main thoracic vessel 5)Have lung cavity 6)Histoly of hemoptysis within two months 7)History of thoracic radiation therapy 8)Tumor invasion to central airway 9)Uncontrolled coagulation disorder or receiving anticoagulant drugs 10)Have inflammatory bowel disease 11)History of thrombosis 12)Have active wounds 13)Uncontrollable hypertension 14)Proteinuria 15)Patient with active infection 16)Symptomatic brain metastases 17)Patient with active double cancers 18)Have active severe heart diseases 19)Patient with impaired mental status 20)Pregnancy 21)Other ineligible status judged by attending doctor
研究者
相似试验
进行中（未招募）
2 期
DTX+RAM PIIon-small cell lung cancerNon-Small Cell Lung CancerJPRN-jRCTs041190077Morise Masahiro32
已完成
不适用
Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patientsnon-small cell lung cancerJPRN-UMIN000025972Gunma University20
已完成
2 期
Phase II trial of docetaxel plus ramucirumab combination therapy in patients with advanced EGFR gene mutation positive advanced stage non-squamous cell nonsmall cell lung cancer (HSR 1701)non-small cell lung cancerJPRN-UMIN000030603Second Division, Department of Internal Medicine, Hamamatsu university school of medicine35
已完成
3 期
Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1-negative or weakly positive advanced non-small-cell lung cancer after disease progression on platinum-based therapy. (EMERALD study) (WJOG10317L)on-small cell lung cancerJPRN-UMIN000031584West Japan Oncology Group420
招募中
2 期
Phase II trail of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903)Gastric cancerJPRN-jRCTs011200010Komatsu Yoshito35